UBS raised the firm’s price target on Cryoport (CYRX) to $11 from $10 and keeps a Buy rating on the shares. The divestiture of CryoPDP is strategically positive, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- Strategic Sale and Partnership Propel CryoPort’s Focus on Cell and Gene Therapy
- CryoPort’s Strategic Shift: Hold Rating Amidst Partnership with DHL and Market Expansion
- CryoPort’s Strategic Sale to DHL: Enhancing Growth and Strengthening Financial Position
- DHL Group acquires Cryopdp from Cryoport, terms not disclosed
- CryoPort Sells CRYOPDP to DHL for $138 Million